Pilot 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Liver Metastases

Not Recruiting

Trial ID: NCT01631318


Patients are invited to participate in a research study of liver perfusion (how blood flows to the liver over time). Researchers hope to learn whether perfusion characteristics of liver metastases may be predictive of response to treatment and whether liver perfusion characteristics can be used to follow response to treatment. Patients were selected as a possible participant in this study because they are identified as having liver metastases

Official Title

Pilot Technical Feasibility Study on 3D Contrast-enhanced Ultrasound Imaging and to Assess Whether Change in Ultrasound 3D Perfusion Pattern Can Predict Treatment Response

Stanford Investigator(s)

Aya Kamaya, MD
Aya Kamaya, MD

Professor of Radiology (Body Imaging)

George A. Fisher Jr.
George A. Fisher Jr.

Colleen Haas Chair in the School of Medicine


Inclusion Criteria

   - Provides written Informed Consent and is willing to comply with protocol requirements.

   - Has at least 1 focal lesion in liver or kidney

   - Patient may be (i) in the process of receiving treatment (1 scan session), (ii) never
   treated (3 scan sessions) or (iii) changing treatment regimen/ type and/or receiving a
   new form of treatment and/or has been on a treatment break ('holiday')(3 scan session)

   - Is at least18 years of age.

Exclusion Criteria

   - Is determined by the Investigator that the subject is clinically unsuitable for the

   - Known right to left cardiac shunt, bidirectional or transient.

   - Hypersensitivity to perflutren.

   - Hypersenstivity to the contrast agent Definity.

   - Pregnant and lactating women


procedure: dynamic contrast-enhanced ultrasound imaging

device: Optical Tracking Device

device: Electromagnetic Tracking Device

drug: Perflutren

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Risa Jiron

New Trial Alerts